Klow™ 80 mg

Research Focus: Extracellular Matrix Biology • Melanocortin Fragment Signaling • Cell Migration
Compound Class: GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg Research Blend

Mechanism of Action

This research blend combines four peptides studied across connective tissue, matrix, cell migration, and melanocortin fragment research.

KPV

KPV is the tripeptide lysine-proline-valine, corresponding to the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH 11-13).

Unlike full-length alpha-MSH, KPV lacks the receptor-binding region required for melanocortin receptor activation, and it does not produce the pigmentation-associated signaling characteristic of MC1R agonists. Its research interest lies elsewhere.

Published experimental work has associated KPV with intracellular signaling rather than cell-surface receptor activation. Studies have reported effects on nuclear factor kappa B signaling in cellular models, and research has examined its uptake through the peptide transporter PepT1, which is expressed in intestinal epithelium.

This makes KPV mechanistically distinct from the melanocortin receptor agonists elsewhere in this catalog: it derives from the same parent hormone but does not act through the same receptor system.

GHK-Cu

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Copper coordination is central to its documented activity. Copper is an essential cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin. Published fibroblast research has additionally reported effects on matrix-associated gene expression and on the balance between matrix metalloproteinases and their tissue inhibitors.

BPC-157

BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of a gastric juice protein. No dedicated receptor has been identified. Experimental studies have associated it with VEGFR2-Akt-eNOS signaling, focal adhesion kinase and paxillin signaling, and the nitric oxide system.

TB-500

TB-500 corresponds to the actin-binding region of thymosin beta-4, the principal G-actin sequestering protein in mammalian cells, which regulates the monomer-filament equilibrium underlying cytoskeletal remodelling and cell motility.

Product Overview

Klow 80 mg is a four-component research blend supplying GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. It extends the Glow formulation with the addition of KPV.

The three shared components address connective tissue and matrix research: copper-dependent matrix enzyme chemistry, growth factor receptor and nitric oxide signaling, and cytoskeletal regulation of cell migration.

KPV introduces a mechanistically separate line of enquiry. As an alpha-MSH C-terminal fragment that does not activate melanocortin receptors, it has been studied for intracellular signaling activity in cellular models, principally in relation to NF-kB.

The blend therefore spans matrix biology, cell migration, and melanocortin fragment research within a single formulation.

None of the four components is an approved therapeutic agent.

Primary Biological Targets & Pathways

• Nuclear factor kappa B (NF-kB) signaling
• PepT1 peptide transporter
• Alpha-MSH C-terminal fragment biology
• Copper(II) binding and coordination chemistry
• Lysyl oxidase and copper-dependent enzymes
• Collagen synthesis and cross-linking
• Matrix metalloproteinases (MMPs)
• Tissue inhibitors of metalloproteinases (TIMPs)
• Extracellular matrix remodelling
• G-actin binding and sequestration
• Actin polymerization dynamics
• Cell migration and motility
• VEGFR2, Akt and eNOS signaling
• Focal adhesion kinase (FAK) and paxillin
• Fibroblast and epithelial cell biology

Primary Research Applications

The component peptides have been investigated in research involving:

• Extracellular matrix biology
• Copper peptide chemistry
• Collagen and elastin cross-linking
• Matrix metalloproteinase regulation
• NF-kB signaling pathways
• Peptide transporter research
• Alpha-MSH fragment structure-activity relationships
• Epithelial cell models
• Cell migration assays
• Cytoskeletal dynamics
• Angiogenesis models
• In vitro wound-closure models

Scientific Evidence

Evidence Level: ★★☆☆☆ (2 of 5)

The evidence base varies across the four components, and a single rating necessarily averages across them.

GHK-Cu has the firmest foundation, resting on well-characterized copper coordination chemistry and the established role of copper in lysyl oxidase-mediated matrix cross-linking, supported by published fibroblast culture work.

KPV has a modest body of cellular and animal literature, principally examining NF-kB signaling and PepT1-mediated transport. Controlled human data are absent.

BPC-157 evidence is predominantly rodent-derived, with mechanisms that remain provisional in the absence of an identified receptor.

Thymosin beta-4’s actin-sequestering role is well established; evidence for the synthetic TB-500 fragment specifically is thinner.

No component has completed controlled human clinical investigation, none holds regulatory approval, and no published research characterizes this four-peptide combination. Combination pharmacology is not additive, and the blend has not been studied as a blend.

Research Highlights

Published research has reported that:

• KPV is the C-terminal tripeptide of alpha-MSH (residues 11-13).
• KPV lacks the melanocortin receptor-binding region and does not act as an MC1R agonist.
• KPV has been associated with NF-kB signaling in cellular models.
• KPV uptake via the PepT1 peptide transporter has been investigated experimentally.
• GHK binds copper(II) with high affinity, forming the GHK-Cu complex.
• Copper is an essential cofactor for lysyl oxidase in collagen and elastin cross-linking.
• GHK-Cu influences matrix-associated gene expression in fibroblast culture.
• BPC-157 is associated in experimental models with VEGFR2, Akt, and eNOS signaling.
• TB-500 corresponds to the actin-binding region of thymosin beta-4.
• Evidence for all components derives predominantly from cellular and animal models.

Scientific Background

The melanocortin system is usually discussed in terms of receptor pharmacology: alpha-MSH and related peptides activating MC1R through MC5R to produce pigmentation, metabolic, behavioural, and autonomic signaling.

KPV occupies a different position within that system. As a C-terminal fragment, it retains part of the alpha-MSH sequence while lacking the core region responsible for receptor binding. Research interest in KPV therefore concerns activity that appears not to require melanocortin receptor engagement – principally intracellular signaling effects reported in cellular models.

This distinction matters when interpreting the literature. Findings relating to alpha-MSH or to melanocortin receptor agonists such as Melanotan II or PT-141 do not transfer to KPV, and vice versa.

The remaining three components address extracellular matrix and cell migration biology. Collagen acquires tensile strength through lysyl oxidase-mediated cross-linking, a copper-dependent process. Matrix turnover reflects the balance between matrix metalloproteinases and their inhibitors. Cell migration through that matrix depends on regulated actin polymerization.

The blend thus combines two largely separate research domains, which should be borne in mind when interpreting results obtained with it.

Research Use Disclaimer

For Laboratory Research Use Only.

This product is intended exclusively for scientific, analytical, and laboratory research. Information presented describes the reported molecular biology of the component peptides and findings from experimental scientific literature, and should not be interpreted as instructions for administration or as expected outcomes in individuals.

None of the component peptides is an FDA-approved therapeutic agent. This product is not intended for human consumption, therapeutic administration, diagnosis, treatment, cure, or prevention of disease.

References

• Dalmasso G, et al. Research examining KPV, PepT1-mediated transport, and NF-kB signaling in epithelial models.
• Brzoska T, et al. Alpha-MSH and related tripeptides: research on melanocortin fragment signaling.
• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences.
• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine.
• Sikiric P, et al. Preclinical research examining BPC-157 and angiogenesis-associated signaling.